TY - JOUR
T1 - Systemic hemodynamic atherothrombotic syndrome (SHATS) – Coupling vascular disease and blood pressure variability
T2 - Proposed concept from pulse of Asia
AU - Kario, Kazuomi
AU - Chirinos, Julio A.
AU - Townsend, Raymond R.
AU - Weber, Michael A.
AU - Scuteri, Angelo
AU - Avolio, Alberto
AU - Hoshide, Satoshi
AU - Kabutoya, Tomoyuki
AU - Tomiyama, Hirofumi
AU - Node, Koichi
AU - Ohishi, Mitsuru
AU - Ito, Sadayoshi
AU - Kishi, Takuya
AU - Rakugi, Hiromi
AU - Li, Yan
AU - Chen, Chen Huan
AU - Park, Jeong Bae
AU - Wang, Ji Guang
N1 - Publisher Copyright:
© 2019
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Hypertension (HTN) is an important risk factor for cardiovascular disease (CVD) but the association between HTN and CVD cannot be explained by average blood pressure (BP) alone. BP variability (BPV) is another important factor, along with the effects of HTN on the vasculature. The concept of systemic hemodynamic atherothrombotic syndrome (SHATS) has been proposed, describing an age-related and synergistic vicious cycle of hemodynamic stress and vascular disease. The importance of SHATS is based on the assumption that the assessment of BPV and arterial disease is likely to provide an effective opportunity to intervene early to reduce progression to HTN in younger patients or to CVD events and organ damage in older patients. In addition to providing an overview of current evidence for the mechanisms and clinical data related to SHATS, this article proposes a new SHATS score for use to diagnose and assess the severity of SHATS. The score includes two components – a BP score and a vascular score – which are multiplied to generate the SHATS score. This reflects the synergistic, rather than additive, effects of BP and vascular disease on target organ damage and CVD events. Although it requires refinement and validation in future studies, early detection of SHATS using tools such as the proposed score, combined with population-based stratification and technology-based anticipation medicine incorporating real-time individual data, has the potential to contribute to meaningful reductions in rates of CVD events and target organ damage.
AB - Hypertension (HTN) is an important risk factor for cardiovascular disease (CVD) but the association between HTN and CVD cannot be explained by average blood pressure (BP) alone. BP variability (BPV) is another important factor, along with the effects of HTN on the vasculature. The concept of systemic hemodynamic atherothrombotic syndrome (SHATS) has been proposed, describing an age-related and synergistic vicious cycle of hemodynamic stress and vascular disease. The importance of SHATS is based on the assumption that the assessment of BPV and arterial disease is likely to provide an effective opportunity to intervene early to reduce progression to HTN in younger patients or to CVD events and organ damage in older patients. In addition to providing an overview of current evidence for the mechanisms and clinical data related to SHATS, this article proposes a new SHATS score for use to diagnose and assess the severity of SHATS. The score includes two components – a BP score and a vascular score – which are multiplied to generate the SHATS score. This reflects the synergistic, rather than additive, effects of BP and vascular disease on target organ damage and CVD events. Although it requires refinement and validation in future studies, early detection of SHATS using tools such as the proposed score, combined with population-based stratification and technology-based anticipation medicine incorporating real-time individual data, has the potential to contribute to meaningful reductions in rates of CVD events and target organ damage.
KW - Blood pressure control
KW - Blood pressure variability
KW - Morning hypertension
KW - Nocturnal hypertension
KW - Synergistic resonance
KW - Systemic hemodynamic atherothrombotic syndrome (SHATS)
UR - http://www.scopus.com/inward/record.url?scp=85076350525&partnerID=8YFLogxK
U2 - 10.1016/j.pcad.2019.11.002
DO - 10.1016/j.pcad.2019.11.002
M3 - Review article
C2 - 31810526
AN - SCOPUS:85076350525
SN - 0033-0620
VL - 63
SP - 22
EP - 32
JO - Progress in Cardiovascular Diseases
JF - Progress in Cardiovascular Diseases
IS - 1
ER -